{
  "id": "5a7237672dc08e987e000008",
  "type": "factoid",
  "question": "Which drug can be reversed with idarucizumab?",
  "ideal_answer": "Idarucizumab is an antibody fragment that specifically reverses dabigatran mediated anticoagulation.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25899749",
    "http://www.ncbi.nlm.nih.gov/pubmed/28416406",
    "http://www.ncbi.nlm.nih.gov/pubmed/27727040",
    "http://www.ncbi.nlm.nih.gov/pubmed/27920714",
    "http://www.ncbi.nlm.nih.gov/pubmed/27625113",
    "http://www.ncbi.nlm.nih.gov/pubmed/26872887",
    "http://www.ncbi.nlm.nih.gov/pubmed/28887767",
    "http://www.ncbi.nlm.nih.gov/pubmed/27224445",
    "http://www.ncbi.nlm.nih.gov/pubmed/28479184",
    "http://www.ncbi.nlm.nih.gov/pubmed/26894245",
    "http://www.ncbi.nlm.nih.gov/pubmed/27268941",
    "http://www.ncbi.nlm.nih.gov/pubmed/27477871",
    "http://www.ncbi.nlm.nih.gov/pubmed/27215215",
    "http://www.ncbi.nlm.nih.gov/pubmed/27568285",
    "http://www.ncbi.nlm.nih.gov/pubmed/26088268",
    "http://www.ncbi.nlm.nih.gov/pubmed/25567155",
    "http://www.ncbi.nlm.nih.gov/pubmed/27317414",
    "http://www.ncbi.nlm.nih.gov/pubmed/25789661",
    "http://www.ncbi.nlm.nih.gov/pubmed/27575900",
    "http://www.ncbi.nlm.nih.gov/pubmed/26095746",
    "http://www.ncbi.nlm.nih.gov/pubmed/27175894",
    "http://www.ncbi.nlm.nih.gov/pubmed/27697436"
  ],
  "snippets": [
    {
      "text": "So far only one reversal agent has been approved by the Food and Drug Administration (FDA), idarucizumab for one of the DOACs i.e., dabigatran. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27215215",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27268941",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES: Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317414",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317414",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317414",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27625113",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27727040",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27727040",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26\u2009s, PT from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27224445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25789661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25789661",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894245",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In ICH related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887767",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab is a reversal agent for dabigatran etexilate.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dabigatran etexilate is an oral thrombin inhibitor that can be reversed by idarucizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION Idarucizumab is a reversal agent for dabigatran etexilate.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab is a humanized monoclonal antibody fragment for reversal of the anticoagulant effects of dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27575900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27568285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27697436",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317414",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab, a monoclonal antibody fragment, directly binds dabigatran etexilate and neutralizes its activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab is an antibody fragment that binds dabigatran with high affinity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27224445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION Reversal of dabigatran etexilate using idarucizumab was safe and successful with no recombinant tissue plasminogen activator interactions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28479184",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26894245",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2015, the humanized monoclonal antibody fragment idarucizumab was approved for rapid (minutes) reversal of anticoagulant effects of dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28416406",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the USA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26872887",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27920714",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab neutralised plasma concentrations of dabigatran, and reversed the effects of the drug on coagulation variables.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25567155",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27317414",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab also reversed the effects of dabigatran and, unlike PCCs, was not associated with over-correction of thrombin generation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25567155",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27477871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This was until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27477871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088268",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27175894",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "dabigatran"
}